Executive Team

Our best-in-class leadership team is expanding, increasing every day the depth of experience and perspective on our growing company. Meet the team:

Steve Saviuk

Mr. Saviuk started his career in accounting at KPMG. He quickly moved to venture capital investing through Manitex Capital Inc., a TSXV-listed company he co-founded over 30 years ago, and which still actively invests in emerging companies with a focus on the life science, renewable energy and sustainable resource sectors. Mr. Saviuk is President and CEO of Manitex Capital inc.

Mr. Saviuk co-founded Valeo Pharma in 2003 and has since served as its President and CEO. Mr. Saviuk transformed Valeo Pharma from its early years as an in-licensor of established brands to a fast growing full service Canadian pharmaceutical company and was also instrumental in the sale of certain assets to Valeant Canada. In addition to Mr. Saviuk’s executive management experience, he is well acquainted with key corporate governance issues having served on numerous boards of both public and private companies.

Mr. Saviuk hold a degree in Business (B.Comm) from Concordia University (Montreal, Qc).

Luc Mainville

In addition to his position with Valeo Pharma, Mr. Mainville is currently the President of Luma Life and Senior Vice-President and Chief Financial Officer of Ortho Regenerative Technologies Inc. He, previously served as Interim Chief Executive Officer at Acerus Pharmaceuticals Corp., Executive Vice President at Cardiome Pharma Corp., President and Chief Executive Officer of Neopharm Labs Inc. and LAB Research Inc.

Mr. Mainville has gained considerable experience throughout his career in senior management roles, including chief financial officer positions for several private and public life science companies such as RTP Pharma, Waratah Pharma, URRMA Biopharma and LAB International. In particular, Mr. Mainville has led or been involved in four distinct IPOs/RTOs, completed more than 20 public financings, and led more than 50 licensing, sale, merger and acquisition transactions. He serves or served as a director for a number of public and private companies in the biotechnology and pharmaceutical industries as well as Chair of the Audit Committee for a number of boards, including that of Acerus Pharmaceuticals, AAA Medic, Enobia Pharma, Powertech Corporation, Cyplasin Biomedical and Chairman of the board of Zucara Therapeutics, Alethia BioTherapeutics and Bioaxone Theratpeutics. He served as Vice-Chairman of BIOTECanada, and also teaches corporate governance and mergers and acquisitions courses at McGill University in Montreal, Quebec. Prior to his career in the life science industry, Mr. Mainville was a Partner at KPMG LLP.

Kyle Steiger

Kyle Steiger is a life science & pharmaceutical industry veteran with over 20 years of proven and diverse experience across specialty pharma, biologic primary care, medical devices, OTC, health policy and reimbursement. Prior to joining Valeo, Kyle served as Vice-President Commercial services at Ashfield, part of UDG Healthcare, and spent more than 19 years at Novartis in various executive positions such as Vice-President Ophthalmology, Vice-President Primary Care and Franchise Head Hematology. Kyle holds a Bachelor of Arts (B.A.), History & Political Science from Brock University.

Guy-Paul Allard

Mr. Allard is a lawyer and Member of the Quebec Bar since 1996. In addition to his position with Valeo Pharma, Mr. Allard is Vice-President, Legal Affairs and Corporate Secretary for Manitex Capital Inc. and Ortho Regenerative Technologies Inc., two affiliates of Valeo Pharma, since April 2016. From 2007 to 2016, he was Partner and Counsel at Dentons, a multinational law firm where he specialized in corporate finance, securities, and mergers and acquisitions. Throughout his career, he has been counsel to several publicly-listed companies on various matters.

Mr. Allard holds a Bachelor’s degree in Business Administration (B.A.A), a Certificate in Law and a Bachelor’s degree in Law (LL.B.) from Laval University (Quebec City).